On July 16, CVS Health rose 3.39% in pre-market trading, trading at $108.50/share, with turnover of $225,300.

The move follows CVS Caremark's announcement of a global settlement with the Federal Trade Commission, resolving all outstanding FTC litigation and investigations related to rebate practices, pharmacy network contracting, and vertical integration issues. The agreement aligns with CVS Caremark's existing affordability and transparency initiatives, including point-of-sale rebate options, flat-dollar copays, copay caps, $0 preventive drug lists, and the TrueCost pricing model.

The settlement eliminates a significant source of regulatory uncertainty that had weighed on the stock. Additionally, multiple Wall Street firms recently raised price targets on CVS Health, including Wells Fargo to $123, Leerink Partners to $119, Goldman Sachs to $116, and RBC to $113, all maintaining bullish ratings. The consensus mean target now stands at approximately $109.96, reflecting growing confidence in the company's turnaround trajectory following consecutive earnings beats and raised guidance.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)